17-Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double-blind, randomized clinical trial

C Andrew Combs, Thomas J Garite, Kimberly Maurel, Kimberly Mallory, Rodney K Edwards, George Lu, Richard Porreco, Anita Das, Obstetrix Collaborative Research Network, C Andrew Combs, Thomas J Garite, Kimberly Maurel, Kimberly Mallory, Rodney K Edwards, George Lu, Richard Porreco, Anita Das, Obstetrix Collaborative Research Network

Abstract

Background: Progestational agents may reduce the risk of preterm birth in women with various risk factors. We sought to test the hypothesis that a weekly dose of 17-hydroxyprogesterone caproate (17P) given to women with preterm rupture of the membranes (PROM) will prolong pregnancy and thereby reduce neonatal morbidity.

Methods: Double-blind, placebo-controlled randomized clinical trial. Women with PROM at 23.0 to 31.9 weeks of gestation were randomly assigned to receive a weekly intramuscular injection of 17P (250 mg in 1 mL castor oil) or placebo (1 mL castor oil). The primary outcome was the rate of continuing the pregnancy until 34.0 weeks of gestation or until documentation of fetal lung maturity at 32.0 to 33.9 weeks of gestation. Planned secondary outcomes were duration of latency period and rate of composite neonatal morbidity. Enrollment of 111 participants per group, 222 total, was planned to yield 80% power to detect an increase in the primary outcome from 30% with placebo to 50% with 17P.

Results: Twelve women were enrolled of whom 4 were randomly assigned to receive 17P and 8 to receive placebo. The trial was terminated prematurely because of two separate issues related to the supply of 17P. No adverse events attributable to 17P were identified.

Conclusion: Because of premature termination, the trial does not have adequate statistical power to evaluate efficacy or safety of 17P in women with PROM. Nonetheless, ethical principles dictate that we report the results, which may contribute to possible future metaanalyses and systematic reviews.

Trial registration: ClinicalTrials.gov: NCT01119963Supported by a research grant from the Center for Research, Education, and Quality, Pediatrix Medical Group, Sunrise, FL.

Figures

Figure 1
Figure 1
Flow diagram showing number of participants at each stage of trial.

References

    1. Caughey AB, Robinson JN, Norwitz ER. Contemporary diagnosis and management of preterm premature rupture of membranes. Rev Obstet Gynecol. 2008;1:11–22.
    1. Mercer BM. Preterm premature rupture of the membranes. Obstet Gynecol. 2003;101:178–193.
    1. Amon E, Lewis SV, Sibai BM, Villar MA, Arheart KL. Ampicillin prophylaxis in preterm premature rupture of the membranes: a prospective randomized study. Am J Obstet Gynecol. 1988;159:539–543.
    1. McGregor JA, French JI, Seo K. Antimicrobial therapy in preterm premature rupture of membranes: results of a prospective, double-blind, placebo-controlled trial of erythromycin. Am J Obstet Gynecol. 1991;165:632–640.
    1. Grable IA, Garcia PM, Perry D, Socol ML. Group B Streptococcus and preterm premature rupture of membranes: a randomized, double-blind clinical trial of antepartum ampicillin. Am J Obstet Gynecol. 1996;175:1036–1042.
    1. Mercer BM, Miodovnik M, Thurnau GR. et al.Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: a randomized controlled trial. JAMA. 1997;278:989–995.
    1. Kenyon SL, Taylor DJ, Tarnow-Mordi W. for the ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomized trial. Lancet. 2001;357:979–988.
    1. Combs CA, McCune M, Clark R, Fishman A. Aggressive tocolysis does not prolong pregnancy or reduce neonatal morbidity after preterm premature rupture of the membranes. Am J Obstet Gynecol. 2004;190:1723–1728.
    1. Mercer BM. Is there a role for tocolytic therapy during conservative mangement of preterm premature rupture of the membranes? Clin Obstet Gynecol. 2007;50:487–496.
    1. Keirse MJNC. Progesterone administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990;97:149–154.
    1. Meis PJ, Klebanoff M, Tom E. et al.Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. New Engl J Med. 2003;348:2379–2385.
    1. Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188:419–424.
    1. DeFranco EA, O'Brien JM, Adair CD. et al.Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:697–705.
    1. Fonseca EB, Celik E, Parra M. et al.Progesterone and the risk of preterm birth among women with a short cervix. New Engl J Med. 2007;357:462–469.
    1. Hassan SS, Romero R, Vidyadhari D. et al.Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18–31.
    1. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007;196:453.e1–453.e4.
    1. Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: A randomized controlled trial. Aust NZ J Obstet Gynaecol. 2008;48:58–63.
    1. Hirota Y, Cha J, Dey SK. Prematurity and the puzzle of progesterone resistance. Nature Med. 2010;16:529–531.
    1. Briery CM, Veillon EW, Klauser CK. et al.Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol. 2011;204:54.e1–54.e5.
    1. CONSORT Group. CONSORT transparent reporting of trials. accessed 27 November 2011.
    1. Cruse AE. Warning letter. accessed 27 November 2011.
    1. Combs CA, Garite T, Maurel K, Das A, Porto M. Obstetrix Collaborative Research Network. Failure of 17-Hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy. Randomized, controlled trial. Am J Obstet Gynecol. 2010;203:248.e1–248.e9.
    1. Combs CA, Garite T, Maurel K, Das A, Porto M. Obstetrix Collaborative Research Network. A randomized, controlled trial of 17-hydroxyprogesterone caproate to prevent preterm birth in twin pregnancy. Am J Obstet Gynecol. 2011;204:221.e1–221.e8.
    1. Editorial. A curious stopping rule from Hoechst Marion Roussel. Lancet. 1999;350:155.
    1. Lievre M, Menard J, Bruckert E. et al.Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001;322:603–605.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe